2012-05-08

Probi and Vifor Pharma sign agreement to launch Probi Digestis^® and
Probi Defendum^® in Switzerland

Probi has signed a distribution and co-marketing agreement with Vifor Pharma, a company of the Galenica Group, to launch Probi’s gut and immune health products on the Swiss pharmacy and drugstore market. The range will be sold under the Vitafor^® umbrella brand and Probi Digestis^® and Probi Defendum^® product brands. The launch will take place in the fourth quarter of 2012 or the first quarter of 2013 and will be supported by strong consumer advertising and one of Switzerland’s best pharmacy sales forces.

Read the full release here

2012-04-26

28% growth in first quarter

Click here to read the release

2012-04-19

Probi and Heinz to launch the first probiotic juice in Australia

Heinz Australia will launch Golden Circle Healthy Life™ Probiotic Juice in May 2012. The product range is based on Probi´s unique immune supporting platform Probi Defendum^®and will create a new category of probiotic juices on the Australian market.

Read the full release here

2012-03-21

Probi signs agreement with a probiotic leader in India

Probi has signed a distribution agreement with USV Limited, a leading Indian Pharmaceutical company. USV will launch Vibact IBS based on the probiotic formulation Probi Digestis, in Q4 2012 in the growing Indian market. The agreement reinforces and strengthens Probi’s existing presence in the large Indian market.

Read the full release here

2012-02-29

Gun-Britt Fransson new Vice President Research & Development at Probi

Probi is expanding its management team through the appointment of Gun-Britt Fransson as Vice President Research & Development. Gun-Britt Fransson, who assumed her new position during February 2012, has held senior positions in the biotechnology and food industries for the past 20 years, most recently as CEO of Alligator Bioscience in Lund.

Read the full release here

2012-01-25

Continued high growth driven by ProbiMage and ProbiFrisk

Preliminary Annual Report 2011

2011-11-03

Probi signs co-development agreement with leading global food company

Probi has entered into a co-development agreement with a leading global food company focusing on joint clinical development of Probi’s immune health platform ProbiDefendum^TM. The objective of the collaboration is to further strengthen the clinical platform of ProbiDefendum^TM in preparation of the application for a health claim within the EU that Probi intends to make. A jointly conducted clinical trial on common colds and immune response will commence in Europe in Q1 2012. Probi’s partner has been granted an exclusive global option to negotiate commercial agreements where Probi currently has no commercial products based on the immune health platform.

Read the full release here

2011-10-19

Continued high growth and US breakthrough for dietary supplements

Read the full release here

2011-08-25

Breakthrough for Probi in U.S. mass retail and mass drug VMS market

Probi has signed one of its most signficant dietary supplement agreements to date with Pharmavite, a leader in the US vitamin, minerals and supplement market (VMS). Pharmavite will launch Probi’s gut health capsules containing Lp299v™ at the beginning of 2012 under the Nature Made^® brand – the leading U.S brand in VMS. The agreement is expected to generate between 5 and 10 MSEK in net revenue for Probi in 2012.

Read the full release here

2011-08-15

The Board of Directos of Probi AB has resolved to utilise the authorisation granted by the Annual General Meeting of Shareholders to repurchase shares in the company.

Read the full release here